Moreover, not only treatment-driven molecular features-based diagnostics require a series of spatiotemporal tumor biopsy analyses, but also the invasive procedures presented only a snapshot of DLBCL heterogeneity, which was inconvenient and unfeasible during long-term follow-up to determine subclonal evolution [15], particularly for high-grade B-cell lymphoma with translocations involving MYC and BCL2 or BCL6, usually referred to as double-hit lymphoma (DHL) [16]., non-invasive biomarkers are urgently required to develop and monitor DLBCL treatment response and disease progression. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.